Business
Once a big player in the ketamine clinic business, the implosion of Field Trip Health illustrates the perils encountered by some companies who entered the psychedelic space early.
In an effort to raise funding for commercialization of MDMA-assisted therapy, MAPS partnered with an investment bank to sell equity in its Public Benefit Corporation.
The CEO of Synthesis speaks out about the recent bankruptcy of the Dutch sister company that left the U.S. practitioner training program in upheaval.
What are the lessons for the psychedelic ecosystem from the collapse of Synthesis Institute?
A clinical trial launched by Sunstone Therapies demonstrated the effectiveness of group therapy as part of psilocybin-assisted therapy for depression.
The organization, including its Dutch retreats business and psychedelic facilitator training programs, plus a 124-acre property in Oregon, filed for bankruptcy this month, leaving its students and employees in limbo.
Industry leaders are exploring alternative IP strategies that can fuel creativity in psychedelic medicine.
The company has closed a $39 million round of financing to optimize existing substances, which they say will make them safer and more effective.
Entrepreneurs opening psilocybin businesses in Oregon face difficulties finding liability insurance and sympathetic landlords.
The company has launched a Community Stakeholder Initiative that allows more people to invest in next-generation MDMA-like medicines.
